Prognostic value of chromosomal translocations in small‐bowel diffuse large B‐cell lymphoma

Abstract

Translocations involving IGH are frequent in cases of small-bowel DLBCL. These translocations may be predictive of a favourable clinical course.

Clinicopathological analysis of primary intestinal diffuse large B‐cell lymphoma: Prognostic evaluation of CD5, PD‐L1, and Epstein‐Barr virus on tumor cells

“…Multivariate analysis of nodal and extranodal DLBCL revealed that patients with small intestinal involvement had worse OS in the rituximab era . Previous studies have shown that surgery combined with chemotherapy and gene translocation involving the immunoglobulin heavy chain is associated with improved outcome in primary intestinal DLBCL, whereas perforation and age ≥65 years are associated with worse prognosis . However, the biological properties or clinicopathological heterogeneity of primary iDLBCL has not been addressed well in the past because of the paucity of well‐documented cases.…”

Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation

“…The macroscopic growth pattern was classified as polypoid, ulcerative, lymphomatous polyposis, diffuse-infiltrating, or mixed by three experienced endoscopists (S.N., T.T., and Y.H.) based on the endoscopic findings in 8 cases and on the surgical excision specimens in 17 cases [6,20,21]. The initial treatment modalities included surgical resection, chemotherapy with a cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP)-based regimen with or without rituximab, radiotherapy, or a combination of them.…”

“…For immunohistochemistry (IHC), we used the primary mouse monoclonal antibodies against CD10 (clone 56C6, 1:100 dilution; Leica Biosystems, Newcastle upon Tyne, UK), bcl-2 (clone 124, 1:100 dilution; Dako), bcl-6 (clone PG-B6p, 1:10 dilution; Dako), MUM1 (clone MUM1p, 1:50 dilution; Dako) and c-myc (clone Y69, 1:100 dilution; Abcam, Cambridge, UK). Samples in which more than 30% of tumor cells were immunoreactive were considered to be positive for CD10, bcl-6 and MUM1 [3,20,21]. Thereafter, tumors were classified as either GCB or non-GCB phenotype according to the algorithm of Hans [25].…”

“…Gene translocation was investigated by interphase fluorescence in situ hybridization (FISH) on FFPE with dual-color, break-apart rearrangement probes for BCL2, BCL6, MYC, IGH, MALT1 (Vysis-Abbott, Des Plaines, IL), IGK and IGL (Cytocell Technologies, Cambridge, UK) as previously described [20,21]. Cases with both IGH and BCL2 rearrangements by break-apart FISH were further investigated by FISH with IGH/BCL2 dual-color, dual fusion translocation probe (Vysis-Abbott, Des Plaines, IL).…”

“…Therefore, it is necessary to establish biomarkers that are cost-effective and useful for diagnosis and prognosis. We previously reported that translocations involving IGH are associated with favorable prognosis in patients with gastric and small bowel DLBCLs [20,21]. In this study, we attempted to classify colorectal DLBCLs according to the recent WHO classification, and to elucidate the clinicopathological significance of molecular subtyping and candidate gene rearrangements.…”